

Neratinib 乳癌患者資助計劃

主診醫生轉介信

Breast Cancer Patient Assistance Program – Neratinib

Doctor's Referral Letter

(Application period: 1 July 2022 – 30 June 2023)

私家診所或私家醫院專用 (For private clinics and private hospitals only)

致:香港乳癌基金會 Neratinib 乳癌患者資助計劃

To: Hong Kong Breast Cancer Foundation

Breast Cancer Patient Assistance Programme – Neratinib

申請人姓名Applicant's name:

申請人聯絡電話

Applicant's contact telephone no.:

處方Neratinib 乳癌藥物劑量(粒數/樽數)

Dosage (No. of tablets/ bottles):

或 預計開始服用Neratinib日期

Or expected Neratinib treatment start date:

診斷

乳癌 Breast Cancer

Diagnosis:

主診醫生

Doctor in-charge:

主診診所 / 醫院

Private Clinic / Hospital in-charge:

主診醫生電話

Doctor-in-charge's telephone no.:

本人同意當申請人成功通過申請後，該病人可以在本診所或醫院免費取得由CANbridge提供的免費Neratinib藥物²

主診醫生簽署

Signature of doctor-in-charge

日期

Date

私家醫院/診所印章

Private Hospital's/ clinic's chop

備註:

1. 如有需要，香港乳癌基金會會聯絡申請人，索取進一步資料。

Note: Hong Kong Breast Cancer Foundation may contact the applicant for further information about the application.

2. Neratinib乳癌患者資助計劃分為「現金補貼計劃」及「買一送一計劃」(二選一)，如申請人有意申請「買一送一計劃」，主診醫生簽署本轉介信後代表同意當申請人成功通過申請後，該病人可以在主診醫生診所或所屬醫院免費取得由CANbridge提供的免費Neratinib藥物，否則香港乳癌基金會未能跟進有關申請。

Breast Cancer Patient Assistance Programme - Neratinib included two schemes 'Cash reimbursement scheme' and 'Buy 1 get 1 free scheme' (Either-Or). For the application of 'Buy 1 get 1 free scheme', the signature of doctor-in-charge means the doctor agree that the applicant is able to get the free bottle of neratinib in the belonged clinic or hospital after the application of 'buy 1 get 1 free scheme' has been approved successfully. If not, the application would not be able to follow up by Hong Kong Breast Cancer Foundation.